Merck posted yet another strong quarter on the back of its cancer therapy Keytruda, in what's becoming almost a routine event for the New Jersey drugmaker.
READ MORESage Therapeutics is doubling down on the "blockbuster potential" of its postpartum depression drug Zurzuvae, expanding professional promotions and taking steps toward a direct-to-consumer ...
READ MORENovartis’ Lutathera is now the first radiopharmaceutical approved for adolescents with a rare cancer found in the gut.
READ MOREMerck KGaA is allocating over €300 million ($321.8 million) to build a new research building at its headquarters in Darmstadt, Germany to study technologies for its life science business.
READ MORE